A randomized cross-over trial of granisetron and dexamethasone versus granisetron alone: The role of dexamethasone on day 1 in the control of cisplatin-induced delayed emesis

被引:13
作者
Sekine, I
Nishiwaki, Y
Kakinuma, R
Kubota, K
Hojo, F
Matsumoto, T
Ohmatsu, H
Yokozaki, M
Kodama, T
机构
[1] Division of Thoracic Oncology, National Cancer Center Hospital East, Kashiwa, Chiba
[2] Division of Thoracic Oncology, National Cancer Center Hospital East, Kashiwa, Chiba 227, 5-1
关键词
granisetron; dexamethasone; antiemetics; delayed emesis; chemotherapy;
D O I
10.1093/oxfordjournals.jjco.a023201
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
We studied the role of dexamethasone (DEX) administered on day 1 in controlling cisplatin-induced delayed emesis. Forty patients were randomly allocated to receive either granisetron (GRN) and DEX on day 1, or the same dose of GRN alone. On days 2-5, all the patients received metoclopramide and DEX. They were corssed over to the other antiemetic regimen with their second course of chemotherapy. Thirty-one patients were evaluable for efficacy. The mean visual analogue scale scores for nausea on days 1 and 2 were 9.1 and 18.8 mm for GRN and DEX, and 16.3 and 28.5 mm for GRN alone, respectively (P<0.05 on day 2). The mean numbers of emetic episodes on days 1-3 were 0.036, 0.46 and 0.36 for GRN and DEX, and 0.39, 0.89 and 0.57 for GRN alone, respectively (P<0.01 on day 1). Hiccups and restlessness were noted in 38% and 33% of cycles, respectively. Addition of DEX to GRN on day 1 thus enhanced the control of delayed emesis.
引用
收藏
页码:164 / 168
页数:5
相关论文
共 12 条
[1]   ADVANCES IN ANTI-EMETIC THERAPY [J].
BAKOWSKI, MT .
CANCER TREATMENT REVIEWS, 1984, 11 (03) :237-256
[2]   REDUCING CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING - CURRENT PERSPECTIVES AND FUTURE POSSIBILITIES [J].
DELFAVERO, A ;
ROILA, F ;
TONATO, M .
DRUG SAFETY, 1993, 9 (06) :410-428
[3]  
GRALLA RJ, 1993, CANCER PRINCIPLES PR, P2338
[4]   2-PERIOD CROSSOVER CLINICAL-TRIAL [J].
HILLS, M ;
ARMITAGE, P .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1979, 8 (01) :7-20
[5]   INCIDENCE, COURSE, AND SEVERITY OF DELAYED NAUSEA AND VOMITING FOLLOWING THE ADMINISTRATION OF HIGH-DOSE CISPLATIN [J].
KRIS, MG ;
GRALLA, RJ ;
CLARK, RA ;
TYSON, LB ;
OCONNELL, JP ;
WERTHEIM, MS ;
KELSEN, DP .
JOURNAL OF CLINICAL ONCOLOGY, 1985, 3 (10) :1379-1384
[6]   CONTROLLING DELAYED VOMITING - DOUBLE-BLIND, RANDOMIZED TRIAL COMPARING PLACEBO, DEXAMETHASONE ALONE, AND METOCLOPRAMIDE PLUS DEXAMETHASONE IN PATIENTS RECEIVING CISPLATIN [J].
KRIS, MG ;
GRALLA, RJ ;
TYSON, LB ;
CLARK, RA ;
CIRRINCIONE, C ;
GROSHEN, S .
JOURNAL OF CLINICAL ONCOLOGY, 1989, 7 (01) :108-114
[7]   COMPARISON OF 3 PROTRACTED ANTIEMETIC REGIMENS FOR THE CONTROL OF DELAYED EMESIS IN CISPLATIN-TREATED PATIENTS [J].
MORENO, I ;
ROSELL, R ;
ABAD, A ;
BARNADAS, A ;
CARLES, J ;
RIBELLES, N ;
SOLANO, V ;
FONT, A .
EUROPEAN JOURNAL OF CANCER, 1992, 28A (8-9) :1344-1347
[8]   A RANDOMIZED CROSS-OVER STUDY OF HIGH-DOSE METOCLOPRAMIDE PLUS DEXAMETHASONE VERSUS GRANISETRON PLUS DEXAMETHASONE IN PATIENTS RECEIVING CHEMOTHERAPY WITH HIGH-DOSE CISPLATIN [J].
OHMATSU, H ;
EGUCHI, K ;
SHINKAI, T ;
TAMURA, T ;
OHE, Y ;
NISIO, M ;
KUNIKANE, H ;
ARIOKA, H ;
KARATO, A ;
NAKASHIMA, H ;
SASAKI, Y ;
TAJIMA, K ;
TADA, N ;
SAIJO, N .
JAPANESE JOURNAL OF CANCER RESEARCH, 1994, 85 (11) :1151-1158
[9]  
SENN S, 1993, CROSSOVER TRIALS CLI
[10]  
SHINKAI T, 1989, JPN J CLIN ONCOL, V19, P40